News

Sarepta’s Risky Gamble: Gene Therapy Stays on Market Despite FDA Request
When three patients die after taking a cutting-edge drug, most companies hit the brakes. Not Sarepta Therapeutics. The ...
Gene therapy maker Sarepta tells FDA it won’t halt shipments despite patient deaths
Drugmaker Sarepta Therapeutics said late Friday it won’t comply with a request from the Food and Drug Administration to halt all shipments of its gene therapy following the ...
Precision Medicine Online3d
Sarepta Cuts 500 Jobs, Refocuses Pipeline on siRNAs in Restructuring Plan
The company will pause several gene therapy development programs, for which it intends to seek partners and other strategic alternatives.
Sarepta Therapeutics to cut 500 jobs amid restructuring
The company aims to focus on high-impact programmes to meet its 2027 financial obligations and support long-term viability.
Fierce Biotech3d
Sarepta pivots to siRNA and lays off 500 staffers as Elevidys gets box warning
Sarepta Therapeutics is laying off 500 staffers, or 36% of its workforce, as part of a strategic restructuring aiming to save $400 million annually. | Sarepta Therapeutics has laid off 500 staffers, ...
Sarepta Therapeutics stock soars after strategic restructuring plan unveiled
Investing.com -- Sarepta Therapeutics (NASDAQ: SRPT) stock soared 36% in after-hours trading Wednesday after the biotech company announced a major strategic restructuring plan designed to ensure ...